Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.

The American journal of pathology - 1 Jul 2010

Benedettini Elisa, Sholl Lynette M, Peyton Michael, Reilly John, Ware Christopher, Davis Lenora, Vena Natalie, Bailey Dyane, Yeap Beow Y, Fiorentino Michelangelo, Ligon Azra H, Pan Bo-Sheng, Richon Victoria, Minna John D, Gazdar Adi F, Draetta Giulio, Bosari Silvano, Chirieac Lucian R, Lutterbach Bart, Loda Massimo

Abstract excerpt

Most non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations respond to tyrosine kinase inhibitor (TKI) therapy. However, about 30% exhibit primary resistance to EGFR TKI therapy. Here we report that Met protein expression and phosphoryla...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Enzyme Activation

Share to In Situ Hybridization, Fluorescence

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 20489150
DOI: 10.2353/ajpath.2010.090863
PMCID: PMC2893683

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20489150-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.PMID 20489150Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype.Semantic proximity Read ↗

Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer.Semantic proximity Read ↗

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer.Semantic proximity Read ↗

EGFR mutation status in brain metastases of non-small cell lung carcinoma.Semantic proximity Read ↗

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies.Semantic proximity Read ↗

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Progress on treatment of MET signaling pathway in non-small cell lung cancer.Semantic proximity Read ↗

Lung Cancer Cell Lines Harboring <i>MET</i> Gene Amplification Are Dependent on Met for Growth and SurvivalSemantic proximity Read ↗

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor DependencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.